Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Thiogenesis Therapeutics Corp TTIPF


Primary Symbol: V.TTI

Thiogenesis Therapeutics, Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is developing sulfur-containing prodrugs that act as precursors with the potential to treat serious pediatric diseases with unmet medical needs. The Company’s lead compound, TTI-0102, is a disulfide, made up of two thiols that lead to two independent cysteamine molecules. Cysteamine is a thiol that has been rigorously studied and tested. It is the active ingredient used in drugs to treat the lysosomal storage disease - (nephropathic) cystinosis. TTI-0102 has been developed to address the obstacles facing thiol-based drugs, their short half-life, gastrointestinal (GI) side effects and dosing limitations. As a prodrug, TTI-0102 is metabolized into cysteamine molecules after it is ingested. The metabolic process acts as a gating mechanism. TTI-0102’s initial applications are for MELAS, Leigh syndrome, Rett syndrome and pediatric non-alcoholic steatohepatitis (NASH).


TSXV:TTI - Post by User

User Avatar Image
(95)
•••
  • MarketMakerssX
Post by MarketMakersson Jan 10, 2025 4:11pm
24 Views
Post# 36398689

Unlocking Rare Disease Potential

Unlocking Rare Disease Potential

Unlocking Rare Disease Potential: Why Thiogenesis Therapeutics (TTI.v) Could Be a Game-Changer

Interested in a unique opportunity in biotech space? Check out Thiogenesis Therapeutics (TTI.v), a clinical-stage company specializing in thiol-active compounds to treat rare mitochondrial dysfunction diseases, targeting an estimated global market of CAD 9.8 billion.

 

With its lead product, TTI-0102—a prodrug of cysteamine designed to improve dosing and reduce side effects—Thiogenesis is poised to make a significant impact in treating conditions like MELAS, Leigh Syndrome, Rett Syndrome, and Pediatric MASH.

 

The Pipeline and Market Opportunity

TTI-0102 has strong patent protection through 2037 across the US, EU, and Japan and is entering pivotal clinical phases. Phase II trials for MELAS and Leigh Syndrome are scheduled for 2025, with market launches anticipated by 2026–2027 and peak sales projected at CAD 4.14 billion. Rett Syndrome and Pediatric MASH trials will follow, offering further upside with sales potential of CAD 1.5 billion for Rett Syndrome alone.

 

Key Catalysts in 2025

The coming year will be transformational for Thiogenesis, with multiple trial starts and regulatory filings expected to provide significant inflection points. Investors should watch for progress on expedited regulatory approvals in the US and EU, which the company aims to leverage to accelerate development timelines for its orphan drug portfolio.

 

Financials and Upside Potential

Valuation Lab estimates a risk-adjusted net present value of CAD 7.5 per share, translating to a staggering 1130% upside. While TTI.v currently holds CAD 4.1 million in cash (as of September 2024), additional funding will be required to achieve critical milestones. Thiogenesis plans to mitigate risks through a commercialization strategy that combines licensing deals for broad indications and targeted sales efforts in orphan drug markets.

 

Investment Considerations

Thiogenesis Therapeutics offers an exciting opportunity for investors with an appetite for biotech innovation. Its focus on rare, high-value diseases, strong IP protections, and strategic regulatory approach position it as a potential leader in the mitochondrial dysfunction treatment space. While challenges remain, including funding and commercialization hurdles, the potential upside is undeniable for those willing to take on the risk.

 

For more information, refer to the full research report: https://www.valuationlab.com/research/

 

Posted on Behalf of Thiogenesis Therapeutics Corp.

 

<< Previous
Bullboard Posts
Next >>